| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.007 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.007 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.081 | 0.007 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.007 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.007 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.45 | 0.007 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.008 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.008 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.11 | 0.008 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.008 |